Who can use VANFLYTA(Quizartinib)?

Quizartinib is a kinase inhibitor indicated for use in combination with standard cytarabine and anthracycline induction chemotherapy and cytarabine consolidation chemotherapy, and as maintenance monotherapy after consolidation chemotherapy, for the treatment of newly diagnosed adult patients with acute myeloid leukemia (AML) who are positive for FLT3 internal tandem duplication (ITD) as detected by an FDA-approved test.